We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
Read MoreHide Full Article
Key Takeaways
Kymera finished the BROADEN2 study enrollment nearly six months early, accelerating KT-621 development.
KYMR expects KT-621 phase IIb AD top-line data by year-end 2026 instead of mid-2027.
KT-621 earlier showed encouraging phase I AD efficacy, biomarker improvements and a favorable safety profile.
Kymera Therapeutics (KYMR - Free Report) shares surged 16.6% on Thursday after announcing enrollment completion in the global phase IIb BROADEN2 study evaluating its lead candidate, KT-621, for moderate to severe atopic dermatitis (AD) nearly six months ahead of schedule. The milestone prompted KYMR to accelerate its top-line data readout timeline to year-end 2026 from its earlier guidance of mid-2027, boosting investor optimism around the development program. AD is a chronic and debilitating skin disease.
The earlier-than-expected enrollment completion significantly shortens the clinical development timeline for KT-621 and positions Kymera to potentially begin phase III studies by mid-2027, subject to regulatory discussions. Faster patient recruitment reflects strong interest from both physicians and patients in a novel oral treatment option for AD while also highlighting KYMR’s operational execution. Investors welcomed the accelerated timeline, viewing it as a step that could bring key efficacy data, subsequent late-stage development and a potential regulatory filing forward.
Phase IIb BROADEN2 Study Evaluates KT-621 in Atopic Dermatitis
The phase IIb BROADEN2 study is a placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of KT-621 in approximately 200 adult and adolescent patients aged 12 to 75 years with moderate to severe AD. The investigational therapy is administered across three dose levels over a 16-week treatment period.
The primary endpoint measures the percent change from baseline in the Eczema Area and Severity Index score, a validated tool for quantifying the extent and severity of AD, at week 16. Secondary endpoints are designed to assess additional efficacy measures, safety, tolerability and quality-of-life outcomes, providing a comprehensive evaluation of KT-621's therapeutic potential in patients with moderate-to-severe AD.
Year to date, Kymera stock has rallied 49.7% compared with the industry’s 1.9% growth.
Image Source: Zacks Investment Research
KT-621 has already generated encouraging early-stage clinical results. In the phase I study in AD patients, the candidate demonstrated deep STAT6 degradation in both blood and skin, accompanied by robust reductions in type II inflammatory biomarkers associated with the disease. KT-621 also delivered meaningful improvements across clinical efficacy measures and patient-reported outcomes in AD, as well as in comorbid asthma and allergic rhinitis. Importantly, the treatment was well-tolerated and exhibited a favorable safety profile, supporting its continued advancement into mid-stage development.
Beyond AD, KT-621 is also being evaluated in the ongoing phase IIb BREADTH study for moderate-to-severe eosinophilic asthma, with top-line data expected in late 2027. The candidate enjoys the FDA’s Fast Track designation for both moderate-to-severe AD and eosinophilic asthma in the United States, a status intended to facilitate the development and review of therapies addressing serious conditions with unmet medical needs.
KT-621 is an investigational, once-daily, first-in-class oral degrader targeting STAT6, the key transcription factor driving IL-4 and IL-13 signaling, which is involved in type II inflammation. While its lead development programs focus on AD and asthma, the mechanism has potential applications across a broad range of type II inflammatory diseases, including chronic obstructive pulmonary disease, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis and bullous pemphigoid, among others.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 123% year to date.
Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.34 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.56. INDV shares have gained 15.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
View the Zacks #1 Rank List
Image: Bigstock
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
Key Takeaways
Kymera Therapeutics (KYMR - Free Report) shares surged 16.6% on Thursday after announcing enrollment completion in the global phase IIb BROADEN2 study evaluating its lead candidate, KT-621, for moderate to severe atopic dermatitis (AD) nearly six months ahead of schedule. The milestone prompted KYMR to accelerate its top-line data readout timeline to year-end 2026 from its earlier guidance of mid-2027, boosting investor optimism around the development program. AD is a chronic and debilitating skin disease.
The earlier-than-expected enrollment completion significantly shortens the clinical development timeline for KT-621 and positions Kymera to potentially begin phase III studies by mid-2027, subject to regulatory discussions. Faster patient recruitment reflects strong interest from both physicians and patients in a novel oral treatment option for AD while also highlighting KYMR’s operational execution. Investors welcomed the accelerated timeline, viewing it as a step that could bring key efficacy data, subsequent late-stage development and a potential regulatory filing forward.
Phase IIb BROADEN2 Study Evaluates KT-621 in Atopic Dermatitis
The phase IIb BROADEN2 study is a placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of KT-621 in approximately 200 adult and adolescent patients aged 12 to 75 years with moderate to severe AD. The investigational therapy is administered across three dose levels over a 16-week treatment period.
The primary endpoint measures the percent change from baseline in the Eczema Area and Severity Index score, a validated tool for quantifying the extent and severity of AD, at week 16. Secondary endpoints are designed to assess additional efficacy measures, safety, tolerability and quality-of-life outcomes, providing a comprehensive evaluation of KT-621's therapeutic potential in patients with moderate-to-severe AD.
Year to date, Kymera stock has rallied 49.7% compared with the industry’s 1.9% growth.
Image Source: Zacks Investment Research
KT-621 has already generated encouraging early-stage clinical results. In the phase I study in AD patients, the candidate demonstrated deep STAT6 degradation in both blood and skin, accompanied by robust reductions in type II inflammatory biomarkers associated with the disease. KT-621 also delivered meaningful improvements across clinical efficacy measures and patient-reported outcomes in AD, as well as in comorbid asthma and allergic rhinitis. Importantly, the treatment was well-tolerated and exhibited a favorable safety profile, supporting its continued advancement into mid-stage development.
Beyond AD, KT-621 is also being evaluated in the ongoing phase IIb BREADTH study for moderate-to-severe eosinophilic asthma, with top-line data expected in late 2027. The candidate enjoys the FDA’s Fast Track designation for both moderate-to-severe AD and eosinophilic asthma in the United States, a status intended to facilitate the development and review of therapies addressing serious conditions with unmet medical needs.
KT-621 is an investigational, once-daily, first-in-class oral degrader targeting STAT6, the key transcription factor driving IL-4 and IL-13 signaling, which is involved in type II inflammation. While its lead development programs focus on AD and asthma, the mechanism has potential applications across a broad range of type II inflammatory diseases, including chronic obstructive pulmonary disease, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis and bullous pemphigoid, among others.
Kymera Therapeutics, Inc. Price and Consensus
Kymera Therapeutics, Inc. price-consensus-chart | Kymera Therapeutics, Inc. Quote
KYMR’s Zacks Rank & Stocks to Consider
Kymera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 123% year to date.
Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.34 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.56. INDV shares have gained 15.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.